Hong Kong · Delayed Price · Currency is HKD TYK Medicines Statistics
Total Valuation
TYK Medicines has a market cap or net worth of HKD 2.56 billion. The enterprise value is 2.50 billion.
| Market Cap | 2.56B |
| Enterprise Value | 2.50B |
Important Dates
The last earnings date was Monday, August 17, 2026.
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TYK Medicines has 384.67 million shares outstanding. The number of shares has increased by 0.71% in one year.
| Current Share Class | 384.67M |
| Shares Outstanding | 384.67M |
| Shares Change (YoY) | +0.71% |
| Shares Change (QoQ) | +2.00% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | 27.94% |
| Float | 235.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 8.52 |
| P/TBV Ratio | 10.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.57.
| Current Ratio | 1.05 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.90 |
Financial Efficiency
Return on equity (ROE) is -70.66% and return on invested capital (ROIC) is -46.94%.
| Return on Equity (ROE) | -70.66% |
| Return on Assets (ROA) | -28.19% |
| Return on Invested Capital (ROIC) | -46.94% |
| Return on Capital Employed (ROCE) | -68.33% |
| Weighted Average Cost of Capital (WACC) | 0.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 173 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.94% in the last 52 weeks. The beta is -0.72, so TYK Medicines's price volatility has been lower than the market average.
| Beta (5Y) | -0.72 |
| 52-Week Price Change | -55.94% |
| 50-Day Moving Average | 6.84 |
| 200-Day Moving Average | 10.51 |
| Relative Strength Index (RSI) | 46.44 |
| Average Volume (20 Days) | 3,710,373 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -406.96M |
| Pretax Income | -252.59M |
| Net Income | -245.31M |
| EBITDA | -392.90M |
| EBIT | -406.96M |
| Earnings Per Share (EPS) | -0.67 |
Balance Sheet
The company has 233.16 million in cash and 172.74 million in debt, with a net cash position of 60.41 million or 0.16 per share.
| Cash & Cash Equivalents | 233.16M |
| Total Debt | 172.74M |
| Net Cash | 60.41M |
| Net Cash Per Share | 0.16 |
| Equity (Book Value) | 301.04M |
| Book Value Per Share | 0.85 |
| Working Capital | 13.57M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 14.21M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TYK Medicines does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.71% |
| Shareholder Yield | -0.71% |
| Earnings Yield | -9.57% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |